EW-7195 is a selective and potent inhibitor of ALK5 (TGFβR1) with an IC50 value of 4.83 nM.EW-7195 has an affinity for ALK5 that is more than 300-fold higher than that of p38α.EW-7195 has an inhibitory effect on TGF-β1-induced Smad signaling, epithelial mesenchymal transition (EMT), and breast cancer metastasis to the lungs.

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:40 mg/mL (98.42 mM)

p38α:1.5 μM (IC50), ALK5:4.83 nM (IC50)

In vitro, EW-7195 efficiently inhibits the epithelial-to-mesenchymal transition (EMT), motility, and invasiveness of breast cancer cells. Following a 1.5-hour treatment at concentrations of 0.5-1 µM, EW-7195 effectively blocks TGF-β1-induced phosphorylation of Smad2, subsequently preventing the nuclear translocation of Smad2/3. Additionally, EW-7195 hinders TGF-β1-induced mesenchymal morphology and transcriptional activation[1].

In both 4T1 orthotopic xenograft and MMTV/cNeu transgenic mice, EW7195 (40 mg/kg; intraperitoneal; three times a week for 3/2.5 weeks) inhibits the development of lung metastasis[1].